The Ayrloom Atlas.

The most quietly impressive cannabinoid lineup currently shipping in New York comes from a 110-year-old apple orchard. Beak & Skiff has been pressing cider on a thousand acres outside Syracuse since 1911. In December 2022, four months after the first adult-use storefronts opened in the state, the fifth generation of the family launched Ayrloom — the first New York company to ship a cannabis-infused beverage into the legal market. They have been quietly accumulating awards (Platinum at the Cannabis Beverage Expo for the Lemonade) and dispensary shelf space ever since.

Ayrloom is an interesting case for DankeSuper because, going into the research for this piece, we expected to find a brand built on functional botanicals — L-theanine, adaptogens, lion's mane, that whole register of additions that have crept into the hemp drinks market over the past two years. We expected we'd need to extend our Cannabinoid Pharmacology Framework with a botanical overlay to score them correctly. We were wrong. Ayrloom's lineup is almost entirely cannabinoid-stacking: THC paired with a single minor cannabinoid (CBG, CBN, CBC, THCV, or CBD), with two narrow exceptions (B-vitamins in Orchard Sunrise, melatonin in Pillow Talk). No adaptogens, no herbs, no caffeine. Just chemistry.

This is, on closer reading, the more rigorous design choice. Functional botanicals in cannabis edibles are a contested category — most consumer doses of L-theanine or ashwagandha in a single gummy aren't clinically meaningful, and they often serve more as marketing copy than pharmacology. Ayrloom skips that move entirely. Their effect taxonomy — Energy, Focus, Bliss, Calm, Rest, Deep Rest — is driven by which minor cannabinoid is paired with THC, in what ratio. The Cannabinoid Pharmacology Framework we published in May handles this directly. Their products are essentially a stress test of whether cannabinoid-only formulation can deliver a distinct, navigable mood spectrum. Our read: yes. Convincingly.

The cannabinoid-stacking model.

Ayrloom's lineup is built on a single design principle: each "effect" is one THC dose plus one supporting cannabinoid. The supporting cannabinoid does the work of shifting the felt experience away from the broad psychoactive baseline of Δ9-THC alone. Pair it with CBG and the experience reads as more energizing and focused. Pair it with CBN and it reads as more sedative. Pair it with THCV and it reads as alert and appetite-suppressing. The pairings come in two ratios: 1:1 (5mg THC + 5mg of the other) for the entry-level SKUs, and "UP" (10mg THC + 5mg of the other) for the standard serving.

The framework's confidence tiers tell the secondary story. Of the six pairings, Ayrloom has chosen four (CBG, CBD, THCV, CBC) where the pharmacology has moderate or strong peer-reviewed evidence in the framework, and two (CBN-led pairings) where the framework explicitly tags the sedation claim as limited. The CBN sleep narrative is the cannabis industry's most- marketed and least-evidenced effect claim — Corroon's 2021 systematic review found no rigorous human trials supporting it. Ayrloom backs the Pillow Talk SKU with 3mg of melatonin, which is evidenced, suggesting they're either aware of CBN's weak human data or independently optimizing for what consumers report works. Dreamweaver doubles down on CBN at 30mg without the melatonin backup; we treat it as a genuine experiment.

The geometry: Ayrloom occupies the middle on purpose.

Plotted out, the lineup makes a deliberate shape. No Turtle. Ayrloom doesn't sell a sub-2.5 mg microdose product (the closest is Lemonade Micro, a hemp-derived 1mg THC / 15mg CBG drink they ship DTC, not in the NY adult-use line). No UFO. Their highest-altitude SKU is Dreamweaver at ~14 mg Δ9-equivalent — squarely Airplane, not crossing into the 25+ mg territory where the framework starts flagging products as novelty/intensity buys. No Sensory at low altitudes either. Sunny Days, the only Delight-quadrant SKU in the line, lives at Airplane.

This isn't an oversight. It's the brand's actual position. Beak & Skiff is a fifth-generation agricultural business with a long cider arm, not a hype-driven exotic chemistry shop. Their products read as carefully engineered midweek consumption: a beverage with dinner, a gummy after work, a sleep gummy at bedtime. Everything sits in the "you will feel this, you will not be embarrassed by it" register. The absence of Turtle and UFO products tells you Ayrloom isn't competing for either the wellness-microdose category or the high-tolerance heavy-user category. They're building for the broad middle of the cannabis consumer market — which, in New York's particular dispensary geography, is also the most lucrative.

Per-pillar: the design rationale.

What this means for the framework.

Ayrloom is a useful proof point for one of the questions we built the Altitude Control framework to answer: can cannabinoid stacking alone deliver a navigable, distinct, mid-altitude effect spectrum, or do you need to add functional botanicals (L-theanine, ashwagandha, etc.) to differentiate the SKUs? The answer Ayrloom's product line provides: no, you don't. Cannabinoid pairing alone produces seven discrete matrix cells across two pillars and three altitudes. The placements are reproducible from the chemistry. The framework handles them without extension.

This actually clarifies what the botanical-overlay module of Altitude Control needs to do when we eventually build it — it's not for differentiating cannabis-only formulations, which cannabinoid stacking already does cleanly. It's for products where botanicals are actually doing pharmacological work: high-dose adaptogens, meaningful nootropic combinations, hemp products built around L-theanine + caffeine pairings. Cann's beverages, Wynk's seltzers, Mary Jones's higher-dose drinks are all candidates. We'll cover one of those in a future Brand Spotlight.

Until then: Ayrloom is the answer to "what does well-designed pure-cannabinoid formulation look like at scale?" The answer is a 1,000-acre apple orchard outside Syracuse with a great chemistry team and zero marketing pretense.

Where to find Ayrloom in New York.

Ayrloom is in roughly 150+ NY adult-use dispensaries as of June 2026, with the deepest verified breadth at Housing Works Cannabis Co. (Broadway, NoMad) — they stock the full beverage range, gummies in both 1:1 and UP ratios, vapes, tinctures, and topicals. The Travel Agency (Union Square, 5th Ave, Downtown Brooklyn, SoHo) carries Ayrloom across all four locations. Smaller delivery-only operators — Cannadreams, Stoops, Torches, The Hemp Social Co. — carry the drinks and gummies primarily.

Pricing at Housing Works as of fetch: $5 per UP can (12oz), $18 per 1:1 gummy pack (50mg total), $25 per UP gummy pack (100mg total), $45 for the all-in-one 1g vape disposables (Cereal Milk, ATF, Pink Rozay confirmed in stock), $60 for High Dose Drops (1000mg THC tincture), $55 for the topical balms (Restore, Rescue, Revive). For the canonical authoritative list, ayrloom.com/pages/where-to-buy-new-york-dispensaries is the source.